Telehealth Reviews

Calibrate review 2026: what $199 a month buys, and what it does not

By the US Health Digest editorial team · Published September 2, 2026 · Every claim linked to its primary source

Calibrate's pricing page, read September 2, 2026, says “$199/MONTH*” with an “Initial 3-month commitment required” that “brings your total commitment cost to $597” — not the $1,500–$1,999 a year 2026 review sites still repeat, which is its 2023–2024 structure. Medication is excluded: lab tests and prescriptions “are not included in the membership cost.” Twelve months of fee is $2,388, the highest service layer of the six programmes priced below. US Health Digest has no affiliate or commercial relationship with Calibrate Health, Inc.

This page reports what company documents, dockets and trials say. It is not advice to join, leave, start or stop anything.

What Calibrate sells, in its own words

The live domain is joincalibrate.com; calibrateme.com does not resolve. The product is called the Metabolic Reset. The pricing page lists what the fee covers: “A 20-minute video clinician visit including lab work review,” “Ongoing access to your Medical and Support Teams,” “Support navigating medication insurance coverage,” “1:1 video coaching sessions,” a curriculum “focused on food, exercise, sleep, and emotional health,” app tracking tools, and a welcome kit with “Personalized smart scale that connects to the Calibrate app.”

The cadence is published on the How It Works page as four named phases — Learning (months 0–3), Practicing (3–6), Setting and Reinforcing (6–9), Sustaining (9+) — with coaching “every other week” and, per the FAQ, sessions of 15 minutes. The clinicians prescribe branded GLP-1s: the same page names “tirzepatide, semaglutide and dulaglutide” under the brands Zepbound®, Wegovy®, Ozempic®, Mounjaro® and Foundayo®. Nothing compounded is named anywhere we read, which distinguishes Calibrate from the products in our Mochi Health review and from most of the market in our compounded versus branded explainer.

So the year is real, but the contract is not. The Membership Terms & Conditions, last updated October 23, 2025, set “an initial term of three (3) months” after which the agreement “will automatically renew for subsequent one-month terms.” The twelve-month framing survives in the curriculum and in the refund promise; the commitment you sign is a quarter.

The price, and the year the headline hides

The $199 figure is stable and old. Internet Archive captures of the same pricing page show “$199/MONTH*” and the $597 commitment on January 16, 2025 and August 6, 2025. The prices the review sites are still quoting are two structures back: the January 13, 2023 capture shows a one-year price of $1,649, and the February 28, 2024 capture shows “$1,749 One-Time (that's only $146/month).” Anything published in 2026 that reports roughly $1,500–$1,999 for the year is describing a product Calibrate stopped selling.

The arithmetic that follows is the part nobody states. A monthly fee that looks lower than a one-time annual price is not lower if you stay the year the programme is designed around: $199 × 12 = $2,388, which is $639 more than the $1,749 the same company charged for twelve months in early 2024. The three-month floor is $597. Both numbers are Calibrate's own; the multiplication is ours.

That comparison needs its caveat stated, because the two prices are not the same deal. The 2024 $1,749 was a single up-front payment for a committed year, non-refundable except under the published exceptions; the 2026 $199 a month is cancellable after the three-month floor, so a member who leaves at month three pays $597 and never reaches $2,388. The 2024 offer also carried a medication-access refund the current terms do not, and the 2023 capture advertised a 30-minute initial doctor visit against today's 20-minute one. The point is narrow and it is the only one we make: for a member who completes the twelve months the programme is built around, the monthly headline is the more expensive of the two.

Coaching-included versus medication-included: the comparison that decides it

Two programmes can quote wildly different numbers and be selling different things. The axis that matters is what the fee contains. Calibrate's fee is almost entirely service — clinician time, coaching, curriculum, insurance navigation — and it assumes your commercial plan pays for the drug. Ro, Noom Med, Found, Hers and Mochi all exclude medication from the fee too, but most of them publish a cash price you can pay if insurance says no. Calibrate does not publish one.

Read the table the right way round. Calibrate is the most expensive service and, if your commercial plan covers a GLP-1, plausibly the cheapest total — roughly $2,688 for a year at its own $25 copay figure, against $3,576 at the very bottom of Ro's self-pay range. If your plan does not cover it, Calibrate has no published answer and the comparison inverts entirely. That single fact does more work than every price in the table. Our 2026 coverage guide and denial-appeal walkthrough are the place to settle it before you pay anyone.

The Results Money Back Promise, in full

The pricing page's bullet reads “+10% weight loss guaranteed or you're eligible for money back.” That is a marketing claim, and the conditions are on a separate page. The Results Money Back Promise, last updated May 16, 2024, states you “may qualify for a 50% refund of your total paid Membership Fees if you do not achieve a minimum of 10% weight loss at the end of 12 consecutive membership months,” and that any refund “will exclude the cost of your medication, labs, any discounts received, and/or other items and services charged by third parties.” To be eligible you must have signed up after May 16, 2024, self-paid rather than come through an employer, not have taken any prescription weight-loss medication in the twelve months before purchase, completed twelve consecutive months, and complied with the Calibrate Commitment.

In money: you pay $2,388 across the year, and a successful claim returns up to $1,194. The Cancellation Policy of May 17, 2024 confirms the rest — a full refund only within 72 hours of purchase, no refund if Calibrate deems you ineligible, otherwise “the Membership Fees are non-refundable,” and seven calendar days' notice required before your next billing date.

Against that, the trial evidence for what a GLP-1 alone does. In STEP 1, semaglutide 2.4 mg produced a mean 14.9% weight change at 68 weeks (PMID 33567185), and in SURMOUNT-1 tirzepatide reached up to 20.9% at 72 weeks (PMID 35658024). A 10% threshold is below what either drug achieved on average in its registration trial. That is context for the promise, not a prediction about any individual.

Is there a trial? We looked, and here is exactly how

Calibrate's pitch is that year-long coaching added to a GLP-1 beats the drug alone. We searched for randomised evidence on September 2, 2026.

PubMed. Seven queries. (GLP-1 receptor agonist[tiab] OR semaglutide[tiab] OR tirzepatide[tiab] OR liraglutide[tiab]) AND (intensive behavioral therapy[tiab] OR lifestyle intervention[tiab] OR behavioral counseling[tiab] OR health coaching[tiab]) AND randomized controlled trial[pt] AND (obesity[mh] OR weight loss[mh]) returned 36. semaglutide AND intensive behavioral therapy AND randomized returned 4; liraglutide AND intensive behavioral therapy AND randomized returned 10; tirzepatide AND lifestyle intervention AND randomized controlled trial[pt] returned 8; (liraglutide[tiab] OR semaglutide[tiab] OR tirzepatide[tiab]) AND (coaching[tiab]) returned 17; (digital health coaching[tiab]) AND (GLP-1[tiab]) AND randomized returned 0; "Calibrate Health"[Affiliation] returned 0.

The landmark hit is STEP 3 (PMID 33625476), and it runs the other way. Both arms received intensive behavioural therapy — the paper specifies “30 counseling visits” over 68 weeks — and the randomisation was drug versus placebo on top of it: −16.0% against −5.7%, a difference of 10.3 percentage points. STEP 3 measures what the drug adds to coaching. Nothing we found measures what coaching adds to the drug.

ClinicalTrials.gov, API v2. The query AREA[InterventionSearch](coaching OR behavioral intervention OR lifestyle intervention) AND AREA[InterventionSearch](semaglutide OR tirzepatide OR liraglutide) AND AREA[ConditionSearch]obesity, filtered to interventional studies, returned 56 records; we read all 56 titles. The one US trial designed to isolate the question — NCT06009653, a Washington University three-arm randomised study of intensive lifestyle therapy with and without tirzepatide — is registered as WITHDRAWN with enrolment 0. Two small trials elsewhere are running: NCT06836284 (Karolinska Institutet, n=40, a digital tool added to liraglutide or semaglutide against standard care, completion May 2027) and NCT07728669 (Kazakh Academy of Nutrition, n=120, a 12-week digital dietary intervention on top of GLP-1 therapy, primary outcome HbA1c). A sponsor search for “Calibrate” returned 0 studies.

Calibrate's own data. The company publishes a 2026 Results Report, and its Methods section describes the design precisely: “a retrospective analysis of outcomes data from Calibrate members who completed the program with a full dataset available for analysis,” with “Only members with complete datasets” included. There is no control group and no randomisation, and the cohorts shrink sharply — 37,031 members at one year, 11,132 at two, 2,461 at three, 620 at four. The headline averages (16%, 18%, 20% and 21% at 12, 24, 36 and 48 months) are completer means from those cohorts. Stated neutrally: a company-published cohort of completers is real-world evidence, and it cannot separate the effect of coaching from the effect of the drug, or from the effect of being the sort of member who finishes. It is not comparable with the randomised intention-to-treat numbers from STEP 1 or SURMOUNT-1, and we are not comparing them.

Insurance is the load-bearing assumption

Calibrate's insurance page sets out the sequence: prior authorisations “typically takes six to eight weeks, but in some cases can take up to 90 days.” That is slower than Ro's stated 1–2 weeks or Noom's 14 days. Three further conditions are published and consequential. High-deductible plan holders “need to pay through the deductible before your medications are covered.” Members with Medicare, Medicaid or Tricare are excluded outright: the same page says Calibrate is “not set up to accept members who have any form of federal or government insurance, regardless of whether they are willing to pay out of pocket or whether they have additional commercial insurance,” which it attributes to “regulatory restrictions in place around the patient populations that Calibrate doctors are able to treat.” And the programme fee itself is not an insured benefit — “The cost of the Calibrate program is not covered by insurance, however it is HSA/FSA eligible.”

Two separate observations about what the site says if there is no affordable route to the drug. First, the published refund has changed: the January 13, 2023 and February 28, 2024 pricing captures both offered a refund less a $250 fee if Calibrate could not secure a $25-a-month copay within 90 days, and no such medication-access refund appears in the current Cancellation Policy, Membership Terms & Conditions or Results Money Back Promise. Second, and separately, the FAQ answer on that subject is truncated: on the August 6, 2025 capture it ended “in the unlikely scenario that there is no path to a low-cost GLP-1 for you, rest assured we still guarantee results,” and on the live FAQ, medication, how-it-works and member-results pages today it stops mid-clause at “for you,” in the page's own content payload. We do not know why the sentence is truncated — a publishing error is as consistent with it as anything else — and we draw no connection between the truncation and the change to the refund.

What we could not verify

• Any self-pay price. Across thirteen Calibrate pages we fetched, the only dollar figures published anywhere are $199, $597 and $25 (plus a $100 and $75,000 liability cap in the Terms of Use). There is no lab price, no maintenance-dose price, and no cash price for any medication — so a member whose plan denies coverage cannot cost the year in advance from Calibrate's own pages. Our self-pay routes guide carries the manufacturer numbers instead: the Wegovy pill at $149/month for 1.5 mg, $199 for 4 mg since Novo's introductory offer expired on August 31, 2026, and $299 at 9 and 25 mg; Zepbound at $299 to $449.
• The Calibrate Commitment. The Membership Terms incorporate it by reference and say it is “included in the Program curriculum.” It gates the refund. We found no public copy.
• Who the clinicians are. The FAQ answer reads, verbatim, “All of our physicians are US-licensed and board-certified Nurse Practitioners.” Physician and nurse practitioner are different credentials; the page does not resolve which staffs the visits, and no named clinician roster is published.
• Litigation. A CourtListener search on September 2, 2026 returns one federal docket naming Calibrate Health, Inc.: GoodRx Inc. v. Calibrate Health, Inc., No. 2:23-cv-03644 (C.D. Cal.), a commercial dispute between two companies, filed May 12, 2023 under a docketed cause of “28:1332 Diversity-Breach of Contract,” nature of suit “190 Contract: Other.” An answer was filed June 20, 2023 and the case terminated August 3, 2023. We have not read the complaint and do not describe its allegations; an allegation is not a finding, and the docket records no adjudication on the merits. We did not attempt a systematic search of federal or state regulatory records and make no claim about Calibrate's regulatory history in either direction.
• Complaint volumes. Consumer review aggregates about Calibrate exist on third-party platforms and on Calibrate's own site. We do not treat unverified user reports as facts about a company, and we publish no testimonials.

Who the structure fits, on its own description

Reading only what the programme contains: Calibrate is built for someone with commercial or employer insurance that already covers a GLP-1, who wants scheduled human coaching every other week rather than messaging, who can absorb $199 a month on top of copays, and who intends to be there at month twelve — because the refund promise, the curriculum and the published outcome curve are all twelve-month structures. It is not built for anyone on Medicare, Medicaid or Tricare, who is excluded by the company's own insurance page; for anyone who needs to know the cash price before committing, because none is published; or for anyone who took a prescription weight-loss medication in the previous year, who is outside the refund promise by its terms. Whether coaching is worth $2,388 on top of a drug is, on the evidence above, still an open question rather than a settled one — though the durability problem it targets is real, as the regain data in our guide to stopping a GLP-1 shows. Compare structures first: our 2026 comparison of GLP-1 telehealth programmes lays the field out.

Frequently asked questions

How much does Calibrate cost in 2026?

Calibrate's pricing page, read on September 2, 2026, states $199 a month with an initial three-month commitment that it puts at a total of $597. Held for twelve months the fee is $2,388. Lab tests and prescription medications are excluded from the membership cost; Calibrate says GLP-1s for most members with commercial insurance are typically capped at $25 per month after any deductible is met. The $1,500 to $1,999 annual figures circulating in 2026 reviews match Calibrate's older structures: Internet Archive captures show $1,649 in January 2023 and $1,749 in February 2024.

Is medication included in the Calibrate price?

No. The pricing page footnote states that lab tests and prescription medications are not included in the membership cost, and the Membership Terms add that the cost of any medication a Calibrate provider prescribes is not included in the membership fees. Calibrate bills the drug to your commercial insurance and publishes no cash price for any medication or lab panel on any page we fetched.

What does the Calibrate money-back guarantee actually require?

The Results Money Back Promise, last updated May 16, 2024, offers a 50 percent refund of membership fees, excluding medication, labs and discounts, if a member does not reach at least 10 percent weight loss at the end of 12 consecutive membership months. Eligibility requires signing up after May 16, 2024, self-paying rather than joining through an employer, not having taken any prescription weight-loss medication in the 12 months before purchase, completing 12 consecutive months, and complying with the Calibrate Commitment, which is a curriculum document we could not find published publicly. On a $2,388 year the maximum refund is $1,194.

Is there a randomised trial showing coaching plus a GLP-1 beats the GLP-1 alone?

We did not find one. Seven PubMed searches on September 2, 2026 and a ClinicalTrials.gov query returning 56 interventional records surfaced no completed randomised trial that adds a year-long commercial coaching programme to a GLP-1 and compares it against the drug alone. STEP 3 gave intensive behavioural therapy of 30 counselling visits to both arms and randomised the drug, finding minus 16.0 percent against minus 5.7 percent at 68 weeks. The one US trial designed to isolate the question, NCT06009653 at Washington University, is registered as withdrawn with zero enrolment. Calibrate's own 2026 Results Report is a retrospective analysis of members who completed the programme with complete datasets, with no control group.

Can I use Calibrate with Medicare or Medicaid?

No. Calibrate's insurance page states that it is not set up to accept members who have any form of federal or government insurance, regardless of whether they are willing to pay out of pocket or hold additional commercial insurance, and attributes this to regulatory restrictions on the patient populations its doctors can treat.

Sources

• Calibrate Health, Inc. Pricing page — “$199/MONTH*”, the $597 three-month commitment, the inclusions list, the “+10% weight loss guaranteed” bullet and the medication-exclusion footnote. Read September 2, 2026. joincalibrate.com/pricing
• Calibrate Health, Inc. How It Works — the four phases, every-other-week coaching, 15-minute sessions, prescribed molecules and brands. Read September 2, 2026. joincalibrate.com/how-it-works
• Calibrate Health, Inc. FAQs — the $25/month copay characterisation, the HSA/FSA statement, the clinician-credential answer, and the truncated no-low-cost-path answer. Read September 2, 2026. joincalibrate.com/faqs. Insurance page — the prior-authorisation timing, the high-deductible condition and the federal/government-insurance exclusion. Read September 2, 2026. joincalibrate.com/pages/insurance
• Calibrate Health, Inc. Membership Terms & Conditions, last updated October 23, 2025 — three-month initial term, monthly auto-renewal, no refunds once a term is paid, medication excluded from fees, Calibrate Commitment incorporated by reference. Link
• Calibrate Health, Inc. Results Money Back Promise, last updated May 16, 2024 — 50% refund, 10% threshold, 12 consecutive months, five eligibility conditions. Link. Cancellation Policy, last updated May 17, 2024 — 72-hour window, non-refundability, seven days' notice. Link
• Calibrate Health, Inc. 2026 Results Report — Methods and Cohort Demographics; retrospective completer analysis; cohort sizes 37,031 / 11,132 / 2,461 / 620; 16% / 18% / 20% / 21% averages. Retrieved September 2, 2026. PDF
• Internet Archive captures of joincalibrate.com/pricing: January 13, 2023 ($1,649), February 28, 2024 ($1,749 one-time), January 16, 2025 and August 6, 2025 ($199/month, $597).
• Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight: The STEP 3 Randomized Clinical Trial. JAMA 2021;325(14):1403–1413. PMID 33625476; registration NCT03611582.
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). PMID 33567185. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). PMID 35658024.
• ClinicalTrials.gov records NCT06009653 (withdrawn, enrolment 0), NCT06836284 and NCT07728669. Queried September 2, 2026.
• Court records via CourtListener, searched September 2, 2026: GoodRx Inc. v. Calibrate Health, Inc., No. 2:23-cv-03644 (C.D. Cal.) — docketed cause, nature of suit and dates only.
• Competitor figures are carried unchanged from our own verified pages: Ro vs Noom Med vs Found (verified August 26, 2026), Hers review (August 18, 2026 capture), Mochi review (August 30, 2026) and self-pay routes (August 30, 2026).